1356 studies found for:    Recruiting | cancer | United States, Texas
Show Display Options
Download search resultsDownload the search results for:
Recruiting | cancer | United States, Texas (1356 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer
Conditions: Lymphedema;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Vulvar Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Vulvar Cancer;   Stage II Endometrial Carcinoma;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVB Vulvar Cancer
Interventions: Procedure: therapeutic lymphadenectomy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery;   Procedure: study of high risk factors;   Other: questionnaire administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
2 Recruiting Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: elesclomol sodium;   Drug: paclitaxel
3 Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Brenner Tumor;   Fallopian Tube Cancer;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: docetaxel;   Drug: carboplatin;   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
4 Recruiting Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Conditions: Dose Escalation;   Safety;   Preliminary Efficacy;   Advanced Solid Tumors;   Metastatic Breast Cancer;   Advanced Pancreatic Adenocarcinoma;   Metastatic Colorectal Cancer;   Recurrent Glioblastoma Multiforme;   Gastric Cancer;   Gastroesophageal Junction Cancer;   Triple Negative Metastatic Breast Cancer;   Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions: Drug: LDE225;   Drug: BKM120
5 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Biological: bevacizumab
6 Recruiting Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Stage I Ovarian Epithelial Cancer;   Stage I Primary Peritoneal Cavity Cancer;   Stage IA Fallopian Tube Cancer;   Stage IB Fallopian Tube Cancer;   Stage IC Fallopian Tube Cancer;   Stage II Ovarian Epithelial Cancer;   Stage II Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIC Fallopian Tube Cancer;   Stage III Ovarian Epithelial Cancer;   Stage III Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Other: pharmacological study;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Other: quality-of-life assessment;   Drug: carboplatin;   Drug: paclitaxel;   Biological: filgrastim
7 Recruiting Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Behavioral: behavioral dietary intervention;   Behavioral: exercise intervention;   Other: counseling intervention;   Other: educational intervention;   Behavioral: compliance monitoring;   Other: questionnaire administration;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
8 Recruiting TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: Paclitaxel;   Drug: AMG 386 Placebo;   Drug: Carboplatin
9 Recruiting A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Conditions: Neoplasms;   Neoplasms, Ovarian;   Neoplasms, Breast;   Advanced or Refractory Solid Malignancies
Interventions: Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB;   Drug: DOXIL/CAELYX (doxorubicin) Treatment Sequence BA
10 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combinaton With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
11 Recruiting Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer
Conditions: Ovarian Carcinosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Uterine Sarcoma;   Stage I Uterine Sarcoma;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage II Uterine Sarcoma;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: ifosfamide
12 Recruiting Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Conditions: Non-Small-Cell Lung Cancer Stage IIIB;   Non-Small-Cell Lung Cancer Stage IV;   Non-Small-Cell Lung Cancer Metastatic;   Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Biological: bavituximab;   Drug: Docetaxel;   Other: Placebo (for bavituximab)
13 Recruiting Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Conditions: Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
14 Recruiting A Study of LY2228820 for Recurrent Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: LY2228820;   Drug: Carboplatin;   Drug: Placebo;   Drug: Gemcitabine
15 Recruiting Pelvic Exenteration for Gynecologic Malignancy
Conditions: Cervical Cancer;   Endometrial Cancer;   Vaginal Cancer;   Vulvar Cancer;   Gynecologic Cancer
Intervention: Behavioral: Questionnaires
16 Recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: cabozantinib-s-malate;   Drug: paclitaxel;   Other: laboratory biomarker analysis
17 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
18 Recruiting A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Conditions: Solid Tumors and Advanced Endometrial Cancer;   Endometrial Cancer;   Second-line Treatment;   VEGF
Intervention: Drug: TKI258
19 Recruiting Study of Kidney Tumors in Young Patients
Conditions: Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Renal Cell Cancer;   Stage I Wilms Tumor;   Stage II Renal Cell Cancer;   Stage II Wilms Tumor;   Stage III Renal Cell Cancer;   Stage III Wilms Tumor;   Stage IV Renal Cell Cancer;   Stage IV Wilms Tumor;   Stage V Wilms Tumor
Interventions: Other: laboratory biomarker analysis;   Other: cytology specimen collection procedure
20 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Procedure: quality-of-life assessment

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years